During the past decade, Praxisgemeinschaft für Onkologie und Urologie conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Praxisgemeinschaft für Onkologie und Urologie" #1 sponsor was "iOMEDICO AG" with 2 trials, followed by "Hoffmann-La Roche" with 1 trials sponsored, "Ipsen" with 1 trials sponsored, "Martin-Luther-Universität Halle-Wittenberg" with 1 trials sponsored and "Novacea" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Praxisgemeinschaft für Onkologie und Urologie" #1 collaborator was "Roche Pharma AG" with 3 trials as a collaborator and "Bristol-Myers Squibb" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Praxisgemeinschaft für Onkologie und Urologie" are "Prostate Cancer" (2 trials), "Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC" (1 trials), "Advanced Solid Tumors or Hematologic Malignancies" (1 trials), "Advanced or Metastatic Renal Cell Carcinoma" (1 trials) and "Extensive-stage Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Praxisgemeinschaft für Onkologie und Urologie" in a lesser frequency.

Most popular intervention types in "Praxisgemeinschaft für Onkologie und Urologie" are "Drug" (5 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan" (1 trials), "Atezolizumab" (1 trials), "Oxaliplatin, 5FU/LV, Bevacizumab" (1 trials), "Pazopanib+Sorafenib" (1 trials) and "Sorafenib+Pazopanib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Praxisgemeinschaft für Onkologie und Urologie" are 6 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Praxisgemeinschaft für Onkologie und Urologie". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Praxisgemeinschaft für Onkologie und Urologie, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Praxisgemeinschaft für Onkologie und Urologie, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".